Content and data provided by various third parties and Fidelity − Terms of Use

Stock Details

RELATED RESOURCES

News & Events:ACXP

ACURX PHARMACEUTICALS INC

3.92Up 0.085 (2.2164 %)as of 3:59:58pm ET 08/05/2022

Quotes delayed at least 15 min. Log in for real time quote.

Log in for more news Show all article details.Expand all| Hide all article details.Collapse all
  1. Show article details.

    Acurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update

    PR Newswire – 8:01 AM ET 08/04/2022

    STATEN ISLAND, N.Y., Aug. 4, 2022 Acurx Pharmaceuticals, Inc. (ACXP), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 second quarter financial results on Tuesday, August 16, 2022, at 8:30 am ET before the U.S. financial markets open.
  2. Show article details.

    BRIEF-Acurx Announces New Data Presentations From Ongoing Ph2 Clinical Trial Program Of Ibezapolstat For Cdi At The 16Th Biennial Congress Of The Anaerobe Society Of America

    Reuters – 9:13 AM ET 08/02/2022

    Acurx Pharmaceuticals Inc (ACXP): * ACURX ANNOUNCES NEW DATA PRESENTATIONS FROM ONGOING PH2 CLINICAL TRIAL PROGRAM OF IBEZAPOLSTAT FOR CDI AT THE 16TH BIENNIAL CONGRESS OF THE ANAEROBE SOCIETY OF AMERICA Source text for Eikon: Further company coverage:
  3. Show article details.

    Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America

    PR Newswire – 9:00 AM ET 08/02/2022

    STATEN ISLAND, N.Y., Aug. 2, 2022  /PRNewswire/ -- Acurx Pharmaceuticals (ACXP), Inc., a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that new microbiome data from its Phase 2a clinical trial in patients with C. difficile Infection, as well as new in vitro microbiology results generated in 2Q 2022, in each c...
  4. Show article details.

    Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering

    PR Newswire – 8:30 AM ET 07/25/2022

    STATEN ISLAND, N.Y., July 25, 2022 Acurx Pharmaceuticals, Inc. (ACXP), a clinical-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that it has entered into definitive agreements with a single healthcare-focused U.S. institutional investor and certain executives of the Company for the purchase and sale of an aggregate of ...
  5. Show article details.

    BRIEF-Acurx Pharmaceuticals Inc Files For Mixed Shelf Of Up To $50 Mln

    Reuters – 8:52 AM ET 07/01/2022

    Acurx Pharmaceuticals Inc (ACXP): * ACURX PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $50 MILLION - SEC FILING Further company coverage:
  6. Show article details.

    91 Biggest Movers From Friday

    Benzinga – 4:28 AM ET 06/13/2022

    91 Biggest Movers From Friday
  7. Show article details.

    12 Health Care Stocks Moving In Friday's After-Market Session

    Benzinga – 5:48 PM ET 06/10/2022

    This article was generated by Benzinga's automated content engine and reviewed by an editor.
  8. Show article details.

    90 Biggest Movers From Yesterday

    Benzinga – 5:44 AM ET 05/13/2022

    90 Biggest Movers From Yesterday
  9. Show article details.

    BRIEF-Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results And Provides Business Update

    Reuters – 7:09 AM ET 05/11/2022

    Acurx Pharmaceuticals Inc (ACXP): * ACURX PHARMACEUTICALS, INC. REPORTS FIRST QUARTER 2022 RESULTS AND PROVIDES BUSINESS UPDATE. * Q1 LOSS PER SHARE $0.26 Source text for Eikon: Further company coverage:
  10. Show article details.

    Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update

    PR Newswire – 7:01 AM ET 05/11/2022

    STATEN ISLAND, N.Y., May 11, 2022 Acurx Pharmaceuticals (ACXP), Inc. , a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the quarter ended March 31, 2022.
  11. Show article details.

    Earnings Scheduled For May 11, 2022

    Benzinga – 6:23 AM ET 05/11/2022

      ** Great Elm Capital is expected to report earnings for its first quarter. ** Trevena is projected to report earnings for its first quarter. ** Life Time Group Hldgs is likely to report quarterly loss at $0.41 per share on revenue of $356.56 million. ** Endeavor Gr Hldgs is estimated to report quarterly earnings at $0.06 per share on revenue of $66.60 million.
  12. Show article details.

    Earnings Scheduled For March 17, 2022

    Benzinga – 4:54 AM ET 03/17/2022

      ** TransGlobe Energy is estimated to report earnings for its fourth quarter. ** Ikena Oncology is projected to report earnings for its fourth quarter. ** RF Industries is likely to report quarterly earnings at $0.04 per share on revenue of $15.84 million. ** Destination XL Group is estimated to report quarterly earnings at $0.13 per share on revenue of $131.88 million.
Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • May
    10

    ACXP announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Classic Patterns (past 90 days)

PROVIDED BY RECOGNIA, INC.

View All Technical Analysis in Advanced Chart Opens in New Window

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
Copyright 1998–2022 FMR LLC. 
All rights reserved. 
Close
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.